Therapy News and Research

RSS

Physicians and researchers to develop kidney replacement device for children

When children need kidney dialysis because of disease or congenital defects, doctors are forced to adapt adult-size dialysis equipment. No FDA-approved kidney replacement devices exist that are specifically designed for children.

12 Nov 2009

3-D software uses real patient data; offers virtual reality technology for doctors and students

James Oliver picked up an Xbox game controller, looked up to a video screen and used the device's buttons and joystick to fly through a patient's chest cavity for an up-close look at the bottom of the heart.

12 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States

11 Nov 2009

Majority of U.S. Army Special Forces Operators do not seek PTSD treatment

According to a University of the Rockies study, more than half (54.4 percent) of U.S. Army Special Forces Operators exposed to combat would not seek treatment while serving in the Army, even if they were experiencing Posttraumatic Stress Disorder (PTSD) symptoms or psychological distress.

11 Nov 2009

Men more likely to abandon partners diagnosed with cancer

A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact.

11 Nov 2009

States are not taking enough efforts to help smokers quit: American Lung Association

As the debate over health care reform dominates the media and political arena, a new American Lung Association report finds that states aren't doing enough to help smokers quit - and policymakers must fix this in the health care reform process.

11 Nov 2009

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen.

11 Nov 2009

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

11 Nov 2009

World's poorest countries fail to address HIV despite low cost and effective preventive health efforts

A proven and cost-effective strategy for turning the tide on global AIDS still remains significantly underutilized, World Vision warned in advance of World AIDS Day. Efforts to prevent mother-to-baby transmission of HIV must be urgently scaled up in high-prevalence countries to avoid needless infection of children, the Christian humanitarian organization said.

11 Nov 2009

Wounded Warrior Project calls for the Congress to pass the Family Caregiver Legislation

As Veterans Day approaches, Wounded Warrior Project (WWP), a nonprofit organization whose mission is to honor and empower wounded warriors, is urging Congress to pass crucial legislation that will assist the family caregivers of the most severely injured veterans.

11 Nov 2009

AMT's gene therapy successful in treating Duchenne muscular dystrophy

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that it has successfully treated Duchenne muscular dystrophy (DMD) in an animal model with its proprietary gene therapy. The proof of concept studies were performed in collaboration with the group of Professor Irene Bozzoni (University of Rome, La Sapienza, Italy) and demonstrated effectiveness in the heart as well as in skeletal muscles.

11 Nov 2009

Epilepsy Therapy Project invests $100,000 in NeuroTherapeutics Pharma

NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.

11 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Lerner Medical Devices selects QuantumMethod for branding and launching its Levia phototherapy device

QuantumMethod announced today that Lerner Medical Devices, Inc. has selected the firm as agency of record, tasked with branding and launching Levia®, the company's new Personal Targeted Phototherapy™ device for the self-treatment of psoriasis. Levia® enables their patients to target their small area and scalp psoriasis with therapeutic ultraviolet light via proprietary delivery systems designed for precise, fast and safe treatment.

11 Nov 2009

Tips for treating age-related dermatologic concerns

Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike.

11 Nov 2009

Ventricular Assist Device/Destination Therapy certification for Sutter Medical Center, Sacramento

The Joint Commission has awarded Sutter Medical Center, Sacramento the Ventricular Assist Device/Destination Therapy certification, allowing the Sacramento region's only heart transplant program to implant left ventricular assist devices (LVADs) as permanent therapy and not just as bridges to transplant

11 Nov 2009

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

Therapy News and Research

Physicians and researchers to develop kidney replacement device for children

3-D software uses real patient data; offers virtual reality technology for doctors and students

Positive results from Puricore's Vashe Wound Therapy efficacy trial

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

Majority of U.S. Army Special Forces Operators do not seek PTSD treatment

Men more likely to abandon partners diagnosed with cancer

States are not taking enough efforts to help smokers quit: American Lung Association

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

World's poorest countries fail to address HIV despite low cost and effective preventive health efforts

Wounded Warrior Project calls for the Congress to pass the Family Caregiver Legislation

AMT's gene therapy successful in treating Duchenne muscular dystrophy

Epilepsy Therapy Project invests $100,000 in NeuroTherapeutics Pharma

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Lerner Medical Devices selects QuantumMethod for branding and launching its Levia phototherapy device

Tips for treating age-related dermatologic concerns

Ventricular Assist Device/Destination Therapy certification for Sutter Medical Center, Sacramento

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News